BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26859714)

  • 1. A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.
    Baranczak A; Kelly JW
    Curr Opin Chem Biol; 2016 Jun; 32():10-21. PubMed ID: 26859714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis.
    Lindquist SL; Kelly JW
    Cold Spring Harb Perspect Biol; 2011 Dec; 3(12):. PubMed ID: 21900404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein misfolding in disease and small molecule therapies.
    Gomes CM
    Curr Top Med Chem; 2012; 12(22):2460-9. PubMed ID: 23339300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation.
    Vendruscolo M
    Expert Opin Drug Discov; 2023; 18(8):881-891. PubMed ID: 37276120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
    Pain C; Dumont J; Dumoulin M
    Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in targeting protein misfolding diseases.
    Denny RA; Gavrin LK; Saiah E
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1935-44. PubMed ID: 23454013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases.
    Ong DS; Kelly JW
    Curr Opin Cell Biol; 2011 Apr; 23(2):231-8. PubMed ID: 21146391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo aspects of protein folding and quality control.
    Balchin D; Hayer-Hartl M; Hartl FU
    Science; 2016 Jul; 353(6294):aac4354. PubMed ID: 27365453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical kinetics for drug discovery to combat protein aggregation diseases.
    Arosio P; Vendruscolo M; Dobson CM; Knowles TP
    Trends Pharmacol Sci; 2014 Mar; 35(3):127-35. PubMed ID: 24560688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using pharmacological chaperones to restore proteostasis.
    Wang YJ; Di XJ; Mu TW
    Pharmacol Res; 2014 May; 83():3-9. PubMed ID: 24747662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein folding, misfolding, aggregation and their implications in human diseases: discovering therapeutic ways to amyloid-associated diseases.
    Iram A; Naeem A
    Cell Biochem Biophys; 2014 Sep; 70(1):51-61. PubMed ID: 24639112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular chaperone functions in protein folding and proteostasis.
    Kim YE; Hipp MS; Bracher A; Hayer-Hartl M; Hartl FU
    Annu Rev Biochem; 2013; 82():323-55. PubMed ID: 23746257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanochaperone-Based Strategies to Control Protein Aggregation Linked to Conformational Diseases.
    Caballero AB; Gamez P
    Angew Chem Int Ed Engl; 2021 Jan; 60(1):41-52. PubMed ID: 32706460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways to polyglutamine aggregation.
    Robertson AL; Bottomley SP
    Adv Exp Med Biol; 2012; 769():115-24. PubMed ID: 23560307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
    Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
    Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteostasis impairment in protein-misfolding and -aggregation diseases.
    Hipp MS; Park SH; Hartl FU
    Trends Cell Biol; 2014 Sep; 24(9):506-14. PubMed ID: 24946960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecules that target protein misfolding.
    Gavrin LK; Denny RA; Saiah E
    J Med Chem; 2012 Dec; 55(24):10823-43. PubMed ID: 23075044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding.
    Ulloa-Aguirre A; Zariñán T; Conn PM
    Rev Invest Clin; 2015; 67(1):15-9. PubMed ID: 25857579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies.
    Khan AN; Khan RH
    Int J Biol Macromol; 2022 Dec; 223(Pt A):143-160. PubMed ID: 36356861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.